ScholarIQanswers from OpenAlex
Bladder and Urothelial Cancer Treatments
TopicLeading institutions, researchers & key papers
Bladder and Urothelial Cancer Treatments is a topic indexed in ScholarIQ from OpenAlex.
What is known about Bladder and Urothelial Cancer Treatments?
ScholarIQrecord summary
This cluster of papers focuses on the diagnosis, treatment, and management of bladder cancer, particularly urothelial carcinoma. It covers topics such as chemotherapy, cystectomy, neoadjuvant therapy, molecular characterization, metastatic bladder cancer, guidelines for management, and immunotherapy. The papers provide insights into various aspects of bladder cancer research and clinical practice.
How many works does Bladder and Urothelial Cancer Treatments have?
ScholarIQindexed works
Bladder and Urothelial Cancer Treatments has 309 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Bladder and Urothelial Cancer Treatments?
ScholarIQopenalex
The OpenAlex for Bladder and Urothelial Cancer Treatments is on the source record.
What are the most-cited papers on Bladder and Urothelial Cancer Treatments?
ScholarIQmost cited works
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles, Michiel S. van der Heijden, Arjun Vasant Balar, Andrea Necchi, Nancy A. Dawson, Peter H. O’Donnell, Ani Sarkis Balmanoukian, Yohann Loriot, Sandy Srinivas, Margitta Retz, Petros Grivas, Richard W. Joseph, Matthew D. Galsky, Mark T. Fleming, Daniel P. Petrylak, José Luis Perez‐Gracia, Howard A. Burris, Daniel Castellano, Christina Canil, Joaquim Bellmunt, Dean F. Bajorin, Dorothee Nickles, Richard Bourgon, Garrett M. Frampton, Na Cui, Sanjeev Mariathasan, Oyewale O. Abidoye, Gregg Fine, Robert Dreicer
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt, Ronald de Wit, David J. Vaughn, Yves Fradet, Jae‐Lyun Lee, Lawrence Fong, Nicholas J. Vogelzang, Miguel Ángel Climent, Daniel P. Petrylak, Toni K. Choueiri, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, Cora N. Sternberg, Yabing Mai, Christian Poehlein, Rodolfo F. Perini, Dean F. Bajorin
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
J. Alfred Witjes, Harman Max Bruins, Richard Cathomas, Éva Compérat, Nigel C. Cowan, Georgios Gakis, Virginia Hernández, Estefania Linares Espinós, Anja Lorch, Y. Neuzillet, Mathieu Rouanne, George N. Thalmann, Erik Veskimäe, María J. Ribal, Antoine G. van der Heijden
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
J. Alfred Witjes, Thierry Lebrét, Éva Compérat, Nigel C. Cowan, Maria De Santis, H.M. Bruins, Virginia Hernández, Estefanía Linares, James Dunn, Mathieu Rouanne, Y. Neuzillet, Erik Veskimäe, Antoine G. van der Heijden, Georgios Gakis, María J. Ribal
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Thomas Powles, Se Hoon Park, Éric Voog, Claudia Caserta, Begoña P. Valderrama, Howard Gurney, Haralabos P. Kalofonos, Siniša Radulović, Wim Demey, Anders Ullén, Yohann Loriot, Srikala S. Sridhar, Norihiko Tsuchiya, Evgeny Kopyltsov, Cora N. Sternberg, Joaquim Bellmunt, Jeanny B. Aragon‐Ching, Daniel P. Petrylak, Robert J Laliberte, Jing Wang, Bo Huang, Craig B. Davis, Camilla Fowst, Nuno Costa, John A. Blake-Haskins, Alessandra di Pietro, Petros Grivas
Where is Bladder and Urothelial Cancer Treatments research published, and who funds it?
ScholarIQvenues & funding sources
TOP JOURNALS
TOP FUNDERS
National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock
How much of the research on Bladder and Urothelial Cancer Treatments is open access?
ScholarIQopen access share
60%OPEN ACCESS